Stocktoria
XBiotech Inc. XBIT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-04-15
XBiotech Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $4.0M | $18.4M |
| Gross profit | — | — | $0 | $3.4M | $12.6M |
| R&D expense | $47.4M | $37.8M | $32.8M | $31.5M | $28.3M |
| Operating income | -$55.7M | -$42.5M | -$37.5M | -$34.5M | -$25.1M |
| Income tax | $235,000 | -$32,000 | $244,000 | -$688,000 | -$8.0M |
| Net income | -$45.5M | -$38.5M | -$24.6M | -$32.9M | -$17.4M |
| EPS (diluted) | $-1.49 | $-1.26 | $-0.81 | $-1.08 | $-0.58 |
| Operating cash flow | -$39.9M | -$31.0M | -$18.7M | -$14.8M | $69.4M |
| Free cash flow | -$40.2M | -$32.3M | -$19.1M | -$15.4M | $65.9M |
| Cash & equivalents | $125.6M | $172.7M | $200.0M | $157.3M | $237.0M |
| Total assets | $150.1M | $199.1M | $226.6M | $246.1M | $275.2M |
| Total liabilities | $9.7M | $16.8M | $7.8M | $5.7M | $5.8M |
| Shareholders' equity | $140.3M | $182.3M | $218.8M | $240.4M | $269.4M |
Source: SEC EDGAR filings · CIK 0001626878 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.